Palo Alto – June 12, 2017 – Cooley advised Ovid on its $75 million initial public offering of 5,000,000 shares of common stock.
Ovid, which now trades on The NASDAQ Global Select Market as “OVID,” is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders.
This transaction follows a series of life sciences IPOs that Cooley advised on in the first half of the year.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.